lanadelumab

Lanadelumab is a fully human monoclonal antibody used for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older. It works by selectively inhibiting plasma kallikrein, a serine protease involved in the generation of bradykinin, which is responsible for the swelling and pain associated with HAE attacks. By blocking plasma kallikrein activity, lanadelumab reduces bradykinin production and helps prevent HAE symptoms. The drug is administered as a subcutaneous injection and provides sustained control over plasma kallikrein activity[1][5][7]. Lanadelumab was developed to address the underlying pathophysiology of HAE related to C1 esterase inhibitor deficiency or dysfunction[6][8].

Brand names

Takhzyro

Other names

lanadelumab-flyo